94591 ⎘
Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Process For Preparation of Imeglimin and Salts Thereof
#2HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS
#3CLEAVABLE LINKER-CONTAINING IONIZABLE LIPIDS AND LIPID CARRIERS FOR THERAPEUTIC COMPOSITIONS
#4CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2
#5Hydantoin containing deoxyuridine triphosphatase inhibitors
#6Hydantoin containing deoxyuridine triphosphatase inhibitors
#7Compound having isocyanuric skeleton and composition in which said compound is included
#8Hydantoin containing deoxyuridine triphosphatase inhibitors
#9Compound having isocyanuric skeleton and composition in which said compound is included
#10Water-repellent substrate
#11Biguanide compositions and methods of treating metabolic disorders
#12Hydantoin containing deoxyuridine triphosphatase inhibitors
#13Hydantoin containing deoxyuridine triphosphatase inhibitors
#145-HT2B Antagonists
#15Compositions and methods for treating metabolic disorders
#165-HTantagonists
#17Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
#18Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease
#195-HT2B antagonists
#20Honeybee repellents and uses thereof
#21Compositions and methods for treating metabolic disorders
#22Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
#23Biguanide compositions and methods of treating metabolic disorders
#24Honeybee repellents and uses thereof
#25Compounds and methods for treating inflammatory and fibrotic disorders
#26Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization
#27Separation of triazine derivatives enantiomers using tartaric acid
#28Compositions and methods of treating metabolic disorders
#29Compounds and methods for treating inflammatory and fibrotic disorders
#30Biguanide compositions and methods of treating metabolic disorders
#31Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
#32Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives
#33Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
#34NOVEL DIHYDROTRIAZINE DERIVATIVE
#35PROCESS OF ISOLATING ENANTIOMER COMPONENT FROM ENANTIOMER MIXTURES BY PARTICLE-SIZE-CONTROLLED CRYSTALLIZATION
#36PROCESS FOR THE SYNTHESIS OF 3,6-DIHYDRO-1,3,5-TRIAZINE DERIVATIVES
#37Method for the production of 3,6-dihydro-L, 3, 5-triazine derivatives from metformin and paraldehyde derivatives
#38Compounds and methods for treating inflammatory and fibrotic disorders
#39Biguanide and dihydrotriazine derivatives
#40Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
#41Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
#42Series Of New 4,6-Diamino-1,2-Dihydro-1-Aryl-1,3,5-Triazines, Substituted By An Adamantyl Moiety In The Position 2 Of Triazine-Their Corresponding Salts, Isomers,Steroisomers, Enantiomers, Free Bases And The Complexes Of All The Above With Natural Macromolecules And Their Synthetic Derivatives.
#43N-PHENYL-1,1,1-TRIFLUOROMETHANESULFONAMIDE HYDRAZONE DERIVATIVE COMPOUNDS AND THEIR USAGE IN CONTROLLING PARASITES
#44Process for resolving aimines that are useful for the treatment of disorders associated with insulin resistance syndrome
#452,4-diamino-1,3,5-triazine derivatives
#46Compounds for the treatment of inflammatory disorders
#47Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
#48Cyclic compound, process for producing the same, and pest control agent
#49Biphenyl-substituted triazines